Skip to main content

Table 2 Incidence and hazard ratios (HRs) for gout during follow-up and mean SU of diagnosed patients with gout in the five observation-clusters of the MPP cohort

From: The absolute risk of gout by clusters of gout-associated comorbidities and lifestyle factors—30 years follow-up of the Malmö Preventive Project

Cluster number C1 C2 C3 C4 C5
Whole cohort (n= 22,057)
Prevalence 16,063 (72.82) 750 (3.40) 528 (2.39) 3673 (16.65) 1043 (4.72)
SU mean* 288.94 ± 67.35 322.98 ± 78.88 316.17 ± 79.64 328.49 ± 73.77 318.55 ± 92.40
Incident cases with gout (n= 910)
Incident gout 551 (60.54) 53 (5.82) 26 (2.85) 235 (25.82) 45 (4.94)
SU mean° 348.05 ± 72.51 384.35 ± 85.67 357.19 ± 96.18 384.74 ± 77.59 389.17 ± 94.96
Age at gout diagnosis 74.79 ± 6.75 76.92 ± 8.11 74.29 ± 9.67 73.82 ± 7.21 72.73 ± 8.49
Follow-up time 28.22 ± 5.52 25.53 ± 6.15 25.19 ± 7.52 27.42 ± 5.99 23.49 ± 8.36
Incidence and HR for gout
Incidence (95%CI)^ 121.5 (111.8 to 132.1) 276.8 (194.4 to 394.1) 195.5 (133.1 to 287.0) 233.3 (205.3 to 265.1) 183.6 (137.2 to 245.9)
HR-unadjusted (95%CI) 1 2.74 (2.06–3.63) 2.72 (1.83–4.03) 2.18 (1.87–2.54) 2.10 (1.55–2.85)
HR-adjusted (95% CI)γ 1 2.31 (1.73–3.07) 2.41 (1.63–3.58) 2.02 (1.73–2.35) 1.98 (1.46–2.68)
  1. The values are presented as mean ± standard deviation for continuous variables and number (percentages) for categorical variables. Age and the follow-up time are calculated in years. C1 to C5 represent cluster numbers 1 to 5. SU serum urate, HR hazard ratio, 95% CI 95% confidence interval
  2. *Baseline serum urate (μmol/L) for clusters in all individuals
  3. °Baseline serum urate (μmol/L) for incidence gout group
  4. ^Incidence per 100,000 person-years at risk
  5. γAdjusted for age and sex